Leading stem cell and exosome therapy research blog by Cell La Vie, Bangkok. Clinical insights, cost breakdowns, and regenerative treatment guides.
5 MSC and exosome trials for psoriasis have reported completion; three 2026 mechanistic studies reveal novel Ang1/Tie2 angiogenesis mechanisms, engineered exosome-nanoparticle platforms, and culture medium optimization for psoriasis-specific MSC potency.
Read More »A 2026 meta-analysis of 7 randomized trials confirms intradiscal MSC injections reduce chronic back pain and disability significantly. Meanwhile, bioengineered exosome therapies are redefining what cell-free disc regeneration looks like.
Read More »CRISPR-edited MSCs, iPSC-derived cells, combinatorial cell therapy, and exosome-based approaches are transforming PAD/CLI treatment. Six landmark 2026 papers and five active clinical trials reviewed for clinicians and researchers.
Read More »Pulmonary arterial hypertension kills half its patients within five years. 2026 research shows mesenchymal stem cells — especially HO-1-modified and mitochondria-primed MSCs — are reversing the vascular remodeling at the disease’s core. Here’s the science behind the breakthrough.
Read More »A 2026 Phase 1 trial showed that MSC-derived exosomes injected into the ear were safe and improved hearing in patients with sudden sensorineural hearing loss. Here’s what the breakthrough means and when it could be available.
Read More »Stem cell therapy prices range from $2,000 to $100,000 depending on where you go. Here’s what actually drives the cost, what’s included, and how Thailand compares to the US, Australia, and Europe in 2026.
Read More »MSC therapy is offering new hope for IBD patients who don’t respond to conventional biologics. Here’s what the 2026 clinical data shows.
Read More »PRP has its limits. For serious tendon and ligament injuries, stem cells are showing results PRP cannot match.
Read More »A June 2026 study shows that senolytic preconditioning dramatically improves MSC efficacy by removing the SASP factors that suppress tissue repair. Plus: AAT-MSCs reverse diabetes via immune reprogramming, and a phase III MSC trial for meniscal repair reaches completion.
Read More »A 2026 real-world study followed 120 refractory lupus nephritis patients treated with UC-MSCs. Cumulative renal response reached 56.7% at 12 months with low relapse rates and zero severe adverse events. Here’s what clinicians need to know.
Read More »A 36-month clinical trial showed zero adverse events and 57% pain reduction when stem cells were injected into torn rotator cuffs. Here’s what weekend warriors and recreational athletes need to know about MSC therapy for sports injuries.
Read More »